322 related articles for article (PubMed ID: 27140403)
41. Value co-creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema.
Spanò R; Di Paola N; Bova M; Barbarino A
BMC Health Serv Res; 2018 Jul; 18(1):571. PubMed ID: 30029666
[TBL] [Abstract][Full Text] [Related]
42. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
[TBL] [Abstract][Full Text] [Related]
43. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.
Squeglia V; Barbarino A; Bova M; Gravante C; Petraroli A; Spadaro G; Triggiani M; Genovese A; Marone G
Orphanet J Rare Dis; 2016 Sep; 11(1):133. PubMed ID: 27686124
[TBL] [Abstract][Full Text] [Related]
44. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
45. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
46. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
47. Economic burden limiting proper healthcare delivery, management, and improvement of patient outcomes.
Cardarelli WJ
Am J Manag Care; 2018 Aug; 24(14 Suppl):S308-S313. PubMed ID: 30132645
[TBL] [Abstract][Full Text] [Related]
48. Diagnosis and treatment of hereditary angioedema.
Canonica GW; Rossi O
Panminerva Med; 2012 Sep; 54(3):241-53. PubMed ID: 22801442
[TBL] [Abstract][Full Text] [Related]
49. The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews.
Jean-Baptiste M; Itzler R; Prusty S; Supina D; Martin ML
Orphanet J Rare Dis; 2022 Jun; 17(1):232. PubMed ID: 35710442
[TBL] [Abstract][Full Text] [Related]
50. New and evolving therapies for hereditary angioedema.
Barmettler S; Li Y; Banerji A
Allergy Asthma Proc; 2019 Jan; 40(1):7-13. PubMed ID: 30582490
[TBL] [Abstract][Full Text] [Related]
51. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe.
Caballero T; Aygören-Pürsün E; Bygum A; Beusterien K; Hautamaki E; Sisic Z; Wait S; Boysen HB
Allergy Asthma Proc; 2014; 35(1):47-53. PubMed ID: 24268449
[TBL] [Abstract][Full Text] [Related]
52. [Hereditary angioedema. Treatment of acute attacks in Argentina].
Malbrán A; Malbrán E; Menéndez A; Fernández Romero DS
Medicina (B Aires); 2014; 74(3):198-200. PubMed ID: 24918666
[TBL] [Abstract][Full Text] [Related]
53. Life-threatening laryngeal attacks in hereditary angioedema patients.
Piotrowicz-Wójcik K; Porebski G
Otolaryngol Pol; 2020 Mar; 74(2):1-5. PubMed ID: 32308206
[TBL] [Abstract][Full Text] [Related]
54. Current medical management of hereditary angioedema: results from a large survey of US physicians.
Riedl M; Gower RG; Chrvala CA
Ann Allergy Asthma Immunol; 2011 Apr; 106(4):316-322.e4. PubMed ID: 21457880
[TBL] [Abstract][Full Text] [Related]
55. Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema.
Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):317-27. PubMed ID: 21942916
[TBL] [Abstract][Full Text] [Related]
56. C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.
Bewtra AK; Levy RJ; Jacobson KW; Wasserman RL; Machnig T; Craig TJ
Allergy Asthma Proc; 2012; 33(5):427-31. PubMed ID: 23026185
[TBL] [Abstract][Full Text] [Related]
57. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.
Lumry WR; Castaldo AJ; Vernon MK; Blaustein MB; Wilson DA; Horn PT
Allergy Asthma Proc; 2010; 31(5):407-14. PubMed ID: 20929608
[TBL] [Abstract][Full Text] [Related]
58. Assessment on hereditary angioedema burden of illness in Brazil: A patient perspective.
Abdon Barbosa A; de Oliveira Martins R; Martins R; Grumach AS
Allergy Asthma Proc; 2019 May; 40(3):193-197. PubMed ID: 31018895
[No Abstract] [Full Text] [Related]
59. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden.
Nordenfelt P; Dawson S; Wahlgren CF; Lindfors A; Mallbris L; Björkander J
Allergy Asthma Proc; 2014; 35(2):185-90. PubMed ID: 24411585
[TBL] [Abstract][Full Text] [Related]
60. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
